Please login to the form below

Not currently logged in
Email:
Password:

Paul Stockdale joins Oxford BioDynamics as CFO

He takes over from Katie Long at the UK biotech

Paul Stockdale has joined Oxford BioDynamics as its new chief financial officer and as an executive director on the UK biotech’s board.

He takes over from Katie Long, who has returned to her role within Tessera Investment Management, having previously established and led Oxford BioDynamics’ finance function.

Stockdale arrives at the company from e-Therapeutics, where he had been financial controller since 2012, and has also previously served at Deloitte as a senior manager.

A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

15th September 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics